The company laid out a three-pronged strategy focused on immuno-oncology, antibody-drug conjugates as well as small molecules, with four programs set to enter pivotal trials this year.
L-R: Chirfi Guindo, chief marketing officer, human health; Marjorie Green, head of late-stage oncology development; Gregory Lubiniecki, VP late oncology development; Eliav Barr, chief medical officer, Merck Research Laboratories; Dean Li, president, Merck Research Laboratories • Source: Alaric DeArment
